Investing in the biotech or biopharmaceutical industry involves extensive research by investors to determine the nature of the products, the company's strategic advances, and the risks involved if the product doesn't work.
Crowdcreate put together a list of the top European BioTech investors. The goal is to help the Founders find the best investors to target and get introduced to.
How we Rank these Biotech Investors
1.) Peer scoring. We ask the experts and run surveys asking investors, founders, and influencers who rank at the top of their list.
2.) The number of deals or investment size. How active are these investors?
3.) ROI. How good are these investors’ returns on investment? Do they have the Midas touch and spotting the best deals?
4.) Social Influence. When they speak, do people listen?
5.) Community involvement. How active are they in giving back to the community?
Are you a Company?
Looking for a Blockchain Marketing Agency? Crowdcreate is a leading crypto, NFT, web3, and metaverse marketing agency that’s helped some of the top projects in crypto create buzz, grow a digital community, and connect with influencers & investors. We’ve been called one of the best agencies in the world because we have the track record and case studies to prove it. Book a call with our team to learn more.
List of Top 25 European Biotech Investors
Frumtak Ventures manages venture funds Frumtak 1 and Frumtak 2. The LPs of these funds are predominantly pension funds as well as some additional stakeholders in Iceland.Frumtak 1 is fully invested. Frumtak 2 invests in early stage/early revenue companies that are post-seed and show great potential for growth.
Fund+ is an open-ended Fund for long term equity investment in innovative Life Sciences companies with a focus on Belgium.
We want to create sustainable shareholders value, contribute to the development of a leadership position in the Life Sciences sector and generate a tangible, beneficial societal impact.
Established in 1992, Archangels is the longest continuously operating business angel syndicate in the world. Our members invest in innovative start-up and early stage companies in Scotland. Our focus is on IP-rich technology and life-sciences, ranging from software development to biopharmaceuticals and bionics. Current portfolio includes CALCiViS, NCTech, Optoscribe, Reactec and ZoneFox.
ACF Investors was launched in November 2011, it is a private sector entity with clear objectives to boost the quality and quantity of business angel investing in the UK, and to support long-term, high quality jobs in growing companies.
The fund has been designed and established by a consortium of private and public bodies with expertise in business angel investment. It has been created with a grant from the Regional Growth Fund and the British Business Bank, and invests alongside business angel syndicates from across the UK.
Biotech Venture Capital
Innovation is where venture capitalists look for opportunities. This could be drug discovery or scientific breakthroughs. Venture capital are typically known as risky bets but can turn into successful IPO’s or large acquisition. The collective value of deals from angel investments to larger funding rounds can range from hundreds of thousands to billions of dollars.
Investing in the future is exciting. It’s about the facts, numbers, opportunities and ideas, and the people behind them. Our ecosystem offers access to the most exciting asset class; curating connections between highly experienced individuals ready to invest, and people at the forefront of innovation with the talent, drive and determination to succeed.
We build bridges between entrepreneurs’ dreams and successful companies. We enable savvy investors to partner with the best start-up companies.
VI Partners is a Swiss venture capital firm providing university spin-off’s as well as other promising start-up companies with capital, coaching and networks. VI Partners is the advisor to multiple funds.
Playmaker is a dedicated discussion platform that allows you to build your identity and grow your following as a Fantasy Manager.
We Are Human builds and invests in technology enabled companies creating a better world.
Established in London by Johan Brand and Jamie Brooker in 2010, we are most notable for founding Kahoot!, a #LearnTech company whose game-based platform has been played by more than a billion people globally.
Is Biotech a Good investment for 2022?
Further evidence of the group’s strength is that volume flows have rocketed to new all-time highs (see above chart)—even as the Index is well below its 5500 price high from last year. This is evidence of strong buying pressure. I expect that biotechs are positioned to outperform the market for the balance of 2022.
Want to Get Connected to this List?
Crowdcreate is a leading crypto, NFT, web3, and metaverse marketing agency that’s helped some of the top projects in crypto create buzz, grow a digital community, and connect with influencers & investors. We’ve been called one of the best agencies in the world because we have the track record and case studies to prove it. Learn more how we can help you.
Why do biotech companies go public?
By going public, a biotech can access these larger and “cleaner” equity markets, which are essential to building and scaling R&D-intensive businesses over time. Building biotech’s is a long-term journey, and having public investors as partners is therefore critical.
Newton Biocapital is a Venture Capital Fund incorporated in Belgium, focused on financing biotech and life science projects in the “core of Europe” (B, NL, D, F) and Japan for the prevention and treatment of chronic diseases.
Our mission is to support the creation of innovative but affordable solutions that will greatly improve the quality of life of patients suffering from chronic diseases.
ULB: ONE OF THE LARGEST EMPLOYERS IN THE CAPITAL
In terms of direct jobs, with more than 5,000 staff members covering many trades with very diverse characteristics (professors, researchers, project managers, laboratory technicians, accountants, secretaries, electricians, plumbers, painters, social workers, nursery nurses, etc. etc).
European Life Science Investors
This list highlights the top European biotech investors. While investing is mostly a global phenomenon, there are certain jurisdictions and geographic regions that focus on key factors best suited for that niche. Local laws and rules govern certain drugs or medicine that can or cannot be used in an area.
Hasselt University is an independent university which is regionally anchored and has a pronounced international orientation. The university stands for excellence in education, top research in spearhead fields and active engagement in innovation and entrepreneurship. The overall objective is to combine academic excellence with economic and social relevance.
We invest in innovative private early- to mid-stage human Life Science companies that address important medical needs with novel technologies or products backed by compelling science and with differentiated advantages over current treatment options.
Our focus is on Switzerland and surrounding EU countries Germany, Austria, France, Italy and Benelux.
We back and partner with game-changing technology and healthcare companies. We have teams in Asia and in Europe and work alongside associated funds around the world, providing substantial global scale, expertise and market reach.
We are Otrium, the fashion outlet marketplace with hundreds of designer stores all in one app.
We tech-enable designer brands to find an owner for every item they produce. We give brands an online outlet channel and digital tools to smartly connect dynamically-priced end-of-season collections with fashion-lovers. Then we give them the data so they can reproduce most-wanted items.
As a bold investment house founded on the principle that wealth should serve to build the future, Edmond de Rothschild is an independent, family-controlled financial group specialising in Private Banking and Asset Management. This vision of wealth and the opportunities it brings for our clients result in pioneering, visionary, long-term investments.
As at 31 December 2017, it had CHF182 billion in assets under management – with 2,700 employees and 27 offices worldwide.
Sungkyunkwan University (SKKU) established in 1398, the oldest university in Asia is among the top-ranking private universities in Korea. Now in the 21st century, SKKU has modernized, and made substantial advances towards becoming a global leader in research and education.
What makes SKKU different from competitors is that SKKU focuses on nurturing students’ soft power, teaching them to be considerate and communicative so that they can cooperate and communicate highly effectively.
Impact Investing Biotech
The biggest biotech impact usually leads to the largest financial gains. As was the case when the global pandemic of COVID-19 impacted the world, investors poured into companies that were finding solutions that could positively affect people’s lives and get back to business.
Longbow Capital is a leading venture investor in the healthcare, wellbeing and life sciences sectors.
For investors, Longbow can offer tax efficient investing into cutting edge, innovative companies with the potential for high returns.
For companies who are fundraising Longbow can provide capital, connections and experience; in particular for consumer health product businesses as we are a founder member of the Boots Centre for Innovation.
LSP is one of Europe’s largest and most experienced healthcare investment firms. With a track record going back more than 25 years, we have built up an investment house that is dedicated to only one task: seeking, nurturing and growing healthcare investment opportunities with the potential to have a positive impact on society. We believe such opportunities create the most value for all parties.
SambrInvest is a private venture capitalist active in the Charleroi Métropole region. Its purpose is to support and develop SMEs and startups. Through his expertise, he advises entrepreneurs at each stage of their project development, while respecting their managerial autonomy.
Epidarex Capital is a leading transatlantic venture capital firm that invests in early-stage, high growth life science opportunities in under-ventured markets. Epidarex funds ground-breaking research, often building companies from scratch, to address large unmet medical needs with solutions that provide significant benefits to patients.
Biotech Funding
The companies/firms with existing networks or investor relationships typically have the easiest time raising capital. Why? Because they know who is investing, how much they are investing, and what they are interested in. They also have built trust over the years. With Crowdcreate, you can leverage our proprietary database and network of the top investors, influencers, and thought leaders to get connected faster than you could on your own.
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 600 start-ups since 2005.
At Downing Ventures, we invest in the dreams and futures of founders to help them build their companies with expertise as well as funding.
We are a venture capitalist team investing in innovative technology companies and pioneering founders across the globe with early to growth stage funding.
V-Bio Ventures is a venture capital fund that finds, builds and finances young, innovative companies in the life sciences arena. Our fund works closely with Belgium-based VIB, one of the world’s premier life science institutes. We invest throughout Europe in start-up and early-stage companies with high growth potential. We focus on technologies that provide transformational improvements in the biopharmaceutical, pharmaceutical, diagnostics and agricultural sectors.
Novalis Biotech seeds biotechnology and life sciences related companies. Novalis develops innovative investment ideas at the early stage and supports further evolution of the companies, by a combination of our contacts, experience and complementary skills.
Our investment ideas focus on the interaction between bio-informatics and life sciences. We strongly believe in applying innovative information technology to advance prevention, diagnosis, or treatment of disease.
tecnet equity is an Austrian venture capital fund investing in innovative, high-tech startup companies with potential for significant growth. As a bridge between research and market, tecnet helps develop promising inventions into real world products.
Active in the areas of information and communication technologies (ICT), life sciences, industrial technologies, material sciences and environmental technologies, tecnet equity is providing venture capital during seed and early stages.
Why is the biotech sector falling?
Part of the sell-off is due to multiple factors, including concerns over rising interest rates plans. Some analysts are also concerned that biotech stocks have become “overvalued” at the peak of the pandemic. As the infection rates decline in large parts of the world, so too has interest in the company stocks.
Want to Get Connected to this List?
Crowdcreate is a leading crypto, NFT, web3, and metaverse marketing agency that’s helped some of the top projects in crypto create buzz, grow a digital community, and connect with influencers & investors. We’ve been called one of the best agencies in the world because we have the track record and case studies to prove it. Learn more how we can help you.
How do biotech startups make money?
Many biotechs intend to develop their drugs only so far on their own and then basically trade them to a larger drug company in exchange for upfront cash and future royalties. Other companies keep the marketing rights to themselves and build out their own sales force.
Author
